Drug Type Oncolytic virus |
Synonyms R 130, R-130, R130 |
Target |
Action inhibitors |
Mechanism CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), CD86 inhibitors(Cluster of differentiation 86 inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Bone Cancer | Phase 1 | China | 10 Apr 2023 | |
| Osteosarcoma | Phase 1 | China | 10 Apr 2023 | |
| Soft Tissue Sarcoma | Phase 1 | China | 10 Apr 2023 | |
| Bronchogenic Carcinoma | Phase 1 | China | 30 Mar 2023 | |
| Non-Small Cell Lung Cancer | Phase 1 | China | 30 Mar 2023 | |
| Small Cell Lung Cancer | Phase 1 | China | 30 Mar 2023 | |
| Ear Neoplasms | Phase 1 | China | 27 Mar 2023 | |
| Esophageal Carcinoma | Phase 1 | China | 27 Mar 2023 | |
| Laryngeal Neoplasms | Phase 1 | China | 27 Mar 2023 | |
| Nose Neoplasms | Phase 1 | China | 27 Mar 2023 |





